Ascentage Pharma Group Inc.
Clinical trials sponsored by Ascentage Pharma Group Inc., explained in plain language.
Biopharmaceutical company developing targeted cancer therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Cancer combo trial halted before full results
Disease control TerminatedThis early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC